Wechselwirkungen von Mitoxantron

When switching from drugs with prolonged immune effects, such as natalizumab, teriflunomide or mitoxantrone, the duration and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects when initiating GILENYA [see Warnings and Precautions (5.2)] . (Fachinformation zu Fingolimod, Arzneimittelwechselwirkungen)

Coadministration of VOSEVI with BCRP substrates (e.g., methotrexate, mitoxantrone, imatinib, irinotecan, lapatinib, rosuvastatin, sulfasalazine, topotecan) is not recommended [see Clinical Pharmacology (12.3) ]. (Fachinformation zu Sofosbuvir und Velpatasvir, Arzneimittelwechselwirkungen)

Anthracycline Antibiotics High doses of cyclosporine (e.g., at starting intravenous dose of 16 mg/kg/day) may increase the exposure to anthracycline antibiotics (e.g., doxorubicin, mitoxantrone, daunorubicin) in cancer patients. (Fachinformation zu Ciclosporin, Arzneimittelwechselwirkungen)

Cardiac Effects Because of the possible danger of cardiac effects in patients previously treated with daunorubicin or doxorubicin, the benefit-to-risk ratio of mitoxantrone injection therapy in such patients should be determined before starting therapy. (Fachinformation zu Mitoxantron, Warnhinweise)

Cardiac Effects Because of the possible danger of cardiac effects in patients previously treated with daunorubicin or doxorubicin, the benefit-to-risk ratio of mitoxantrone injection therapy in such patients should be determined before starting therapy. (Fachinformation zu Mitoxantron, Warnhinweise)

…(e.g., atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, rosuvastatin, repaglinide, rifampin, simvastatin acid, SN-38 [active metabolite of irinotecan], valsartan) or breast cancer resistance protein (BCRP) (e.g., imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, rosuvastatin, sulfasalazine, topotecan). (Fachinformation zu Eltrombopag, Arzneimittelwechselwirkungen)

Among 112 patients evaluable for safety on the mitoxantrone injection + hydrocortisone arm of the CALGB trial, 18 patients (19%) had a reduction in cardiac function, 5 patients (5%) had cardiac ischemia, and 2 patients (2%) experienced pulmonary edema. (Fachinformation zu Mitoxantron, Warnhinweise)

For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while… (Fachinformation zu Leflunomid, Arzneimittelwechselwirkungen)

When switching from drugs with prolonged immune effects, such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone, consider the duration and mode of action of these drugs because of additive immunosuppressive effects when initiating OCREVUS [see Warnings and Precautions (5.2) ]. (Fachinformation zu Ocrelizumab, Arzneimittelwechselwirkungen)

In a randomized comparative trial of mitoxantrone injection plus low-dose prednisone vs. low-dose prednisone, 7 of 128 patients (5.5 %) treated with mitoxantrone injection had a cardiac event defined as any decrease in LVEF below the normal range, congestive heart failure (n = 3), or myocardial ischemia. (Fachinformation zu Mitoxantron, Warnhinweise)

For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while… (Fachinformation zu Teriflunomid, Arzneimittelwechselwirkungen)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Fachinformation zu Mitoxantron, Arzneimittelwechselwirkungen)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Fachinformation zu Mitoxantron, Arzneimittelwechselwirkungen)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Fachinformation zu Mitoxantron, Arzneimittelwechselwirkungen)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Fachinformation zu Mitoxantron, Arzneimittelwechselwirkungen)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Fachinformation zu Mitoxantron, Arzneimittelwechselwirkungen)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Fachinformation zu Mitoxantron, Arzneimittelwechselwirkungen)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Fachinformation zu Mitoxantron, Arzneimittelwechselwirkungen)

In first-line comparative trials of mitoxantrone injection + cytarabine vs. daunorubicin + cytarabine in adult patients with previously untreated ANLL, therapy was associated with congestive heart failure in 6.5% of patients on each arm. (Fachinformation zu Mitoxantron, Warnhinweise)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Fachinformation zu Mitoxantron, Arzneimittelwechselwirkungen)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Fachinformation zu Mitoxantron, Arzneimittelwechselwirkungen)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Fachinformation zu Mitoxantron, Arzneimittelwechselwirkungen)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Fachinformation zu Mitoxantron, Arzneimittelwechselwirkungen)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Fachinformation zu Mitoxantron, Arzneimittelwechselwirkungen)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Fachinformation zu Mitoxantron, Arzneimittelwechselwirkungen)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Fachinformation zu Mitoxantron, Arzneimittelwechselwirkungen)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Fachinformation zu Mitoxantron, Arzneimittelwechselwirkungen)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Fachinformation zu Mitoxantron, Arzneimittelwechselwirkungen)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Fachinformation zu Mitoxantron, Arzneimittelwechselwirkungen)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Fachinformation zu Mitoxantron, Arzneimittelwechselwirkungen)

• Prior treatment with an immunosuppressant (e.g., mitoxantrone, azathioprine, methotrexate, cyclophosphamide, mycophenolate mofetil). (Fachinformation zu Natalizumab, Warnhinweise und Vorsichtsmaßnahmen)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Fachinformation zu Mitoxantron, Arzneimittelwechselwirkungen)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Fachinformation zu Mitoxantron, Arzneimittelwechselwirkungen)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (Fachinformation zu Mitoxantron, Arzneimittelwechselwirkungen)